The US Food and Drug Administration relied on a 2015 immunogenicity study to grant Bavarian Nordic A/S’ monkeypox vaccine Jynneos an emergency use authorization for administration by intradermal injection, a strategy that will increase the total number of doses available by up to five fold. (Also see "Monkeypox Vaccine: US FDA Eyes Dose-Sparing Strategy For Jynneos" - Pink Sheet, 4 August, 2022.)
One reason the agency may have been comfortable using immunogenicity data to grant the EUA for adults at high-risk of...







